JP2021523906A5 - - Google Patents
Info
- Publication number
- JP2021523906A5 JP2021523906A5 JP2020563980A JP2020563980A JP2021523906A5 JP 2021523906 A5 JP2021523906 A5 JP 2021523906A5 JP 2020563980 A JP2020563980 A JP 2020563980A JP 2020563980 A JP2020563980 A JP 2020563980A JP 2021523906 A5 JP2021523906 A5 JP 2021523906A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- pharmaceutical composition
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024130558A JP2024160301A (ja) | 2018-05-14 | 2024-08-07 | Ｌｉｆに対する抗体及びそれらの投与形態 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382327 | 2018-05-14 | ||
| EP18382327.7 | 2018-05-14 | ||
| EP18382359 | 2018-05-25 | ||
| EP18382359.0 | 2018-05-25 | ||
| EP19382208 | 2019-03-26 | ||
| EP19382208.7 | 2019-03-26 | ||
| EP19382331 | 2019-05-03 | ||
| EP19382331.7 | 2019-05-03 | ||
| PCT/IB2019/000541 WO2019220204A2 (en) | 2018-05-14 | 2019-05-13 | Antibodies against lif and dosage forms thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024130558A Division JP2024160301A (ja) | 2018-05-14 | 2024-08-07 | Ｌｉｆに対する抗体及びそれらの投与形態 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021523906A JP2021523906A (ja) | 2021-09-09 |
| JP2021523906A5 true JP2021523906A5 (OSRAM) | 2022-05-20 |
| JP7536654B2 JP7536654B2 (ja) | 2024-08-20 |
Family
ID=67902550
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020563980A Active JP7536654B2 (ja) | 2018-05-14 | 2019-05-13 | Ｌｉｆに対する抗体及びそれらの投与形態 |
| JP2024130558A Pending JP2024160301A (ja) | 2018-05-14 | 2024-08-07 | Ｌｉｆに対する抗体及びそれらの投与形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024130558A Pending JP2024160301A (ja) | 2018-05-14 | 2024-08-07 | Ｌｉｆに対する抗体及びそれらの投与形態 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220064279A1 (OSRAM) |
| EP (1) | EP3794031A2 (OSRAM) |
| JP (2) | JP7536654B2 (OSRAM) |
| KR (1) | KR20210008514A (OSRAM) |
| CN (1) | CN112638941A (OSRAM) |
| AU (1) | AU2019269131B2 (OSRAM) |
| CA (1) | CA3099406A1 (OSRAM) |
| MA (1) | MA52021A (OSRAM) |
| SG (1) | SG11202011170YA (OSRAM) |
| WO (1) | WO2019220204A2 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3806899A2 (en) * | 2018-06-18 | 2021-04-21 | MedImmune Limited | Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer |
| SG11202108627SA (en) | 2019-02-18 | 2021-09-29 | Lilly Co Eli | Therapeutic antibody formulation |
| CN114929741A (zh) * | 2019-12-04 | 2022-08-19 | 免疫医疗有限公司 | 针对lif的抗体及其用途 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
| KR100940380B1 (ko) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| ES2363358B1 (es) | 2009-04-03 | 2012-06-21 | FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al | Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable. |
| EP2371860A1 (en) | 2010-04-05 | 2011-10-05 | Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation |
| JP2017527582A (ja) | 2014-09-10 | 2017-09-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｋ−Ｒａｓによって媒介されるシグナリング経路および悪性疾患の抗ｈＬＩＦ抗体によるターゲティング方法 |
| JP2017534617A (ja) | 2014-10-21 | 2017-11-24 | アブリンクス エン．ヴェー． | Ｉｌ−６ｒ関連疾患の処置 |
| EP3173483A1 (en) * | 2015-11-27 | 2017-05-31 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Agents for the treatment of diseases associated with undesired cell proliferation |
| US10583191B2 (en) * | 2016-12-19 | 2020-03-10 | Mosaic Biomedicals Slu | Antibodies against LIF and uses thereof |
| WO2019197903A1 (en) * | 2018-04-12 | 2019-10-17 | Mosaic Biomedicals Slu | Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer |
-
2019
- 2019-05-13 SG SG11202011170YA patent/SG11202011170YA/en unknown
- 2019-05-13 JP JP2020563980A patent/JP7536654B2/ja active Active
- 2019-05-13 CA CA3099406A patent/CA3099406A1/en active Pending
- 2019-05-13 MA MA052021A patent/MA52021A/fr unknown
- 2019-05-13 WO PCT/IB2019/000541 patent/WO2019220204A2/en not_active Ceased
- 2019-05-13 EP EP19765782.8A patent/EP3794031A2/en not_active Withdrawn
- 2019-05-13 AU AU2019269131A patent/AU2019269131B2/en not_active Ceased
- 2019-05-13 US US17/055,279 patent/US20220064279A1/en not_active Abandoned
- 2019-05-13 CN CN201980046565.4A patent/CN112638941A/zh active Pending
- 2019-05-13 KR KR1020207035617A patent/KR20210008514A/ko not_active Ceased
-
2024
- 2024-08-07 JP JP2024130558A patent/JP2024160301A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12453771B2 (en) | Methods of treating cancer using anti-CD137 antibodies | |
| CN114716552B (zh) | 人源化、小鼠或嵌合抗cd47单克隆抗体 | |
| EP1735348B1 (en) | Human anti-epidermal growth factor receptor antibody | |
| JP2024079823A (ja) | ＥｒｂＢ－２およびＥｒｂＢ－３に結合する抗体 | |
| EP2707028B1 (en) | C-kit antibodies and uses thereof | |
| TWI381848B (zh) | 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物 | |
| CN101868478B (zh) | 巨噬细胞刺激蛋白质受体(ron)的抑制及其治疗方法 | |
| JP2021502980A (ja) | Ａｔｐ放出の効果の強力化 | |
| KR102360967B1 (ko) | 신규 항-네트린-1 항체 | |
| JP2023546743A5 (OSRAM) | ||
| EP3825330A1 (en) | Anti-cd117 antibodies and methods of use thereof | |
| JP2008508858A (ja) | マクロファージ−刺激タンパク質受容体（ｒｏｎ）の阻害 | |
| CN114829405B (zh) | 抗bcma/抗4-1bb双特异性抗体及其用途 | |
| CN101233155B (zh) | 人抗表皮生长因子受体抗体 | |
| US11512134B2 (en) | Anti-CD137 antibodies | |
| EP3778647A1 (en) | Antibody specifically binding to erbb3 and use thereof | |
| HK40081907A (en) | Anti-cd137 antibodies | |
| WO2025117871A1 (en) | Bispecific tetravalent antibody targeting her2 and her3 | |
| JP2021533084A5 (OSRAM) | ||
| WO2025117872A1 (en) | Bispecific antibody-like protein and methods of making and using thereof | |
| CN107207590A (zh) | 抗cxcl12抗体分子及其用途 | |
| HK40019208B (en) | Anti-cd137 antibodies | |
| EA043217B1 (ru) | Анти-cd137 антитела | |
| HK1262017A1 (en) | Humanized, mouse or chimeric anti-cd47 monoclonal antibodies | |
| HK1262017B (en) | Humanized, mouse or chimeric anti-cd47 monoclonal antibodies |